Metabolic Disorder Treatment

Eliglustat (OLEPTISS) Tablet

$139.00

Eliglustat Oleptiss FCT 180/360 MG Tablet is a medication used in the treatment of Gaucher disease, a rare genetic disorder characterized by the deficiency of the enzyme glucocerebrosidase. It contains eliglustat as its active ingredient, a substrate reduction therapy that reduces the accumulation of glucocerebroside in cells

Strength	Choose an option180mg360mg
	Clear

Quantity

Eliglustat (OLEPTISS) Tablet quantity

Add to cart

Sku:

N/A

Tag:

Eliglustat OLEPTISS

Description

Eliglustat Oleptiss FCT 180/360 MG Tablet is a medication used in the treatment of Gaucher disease, a rare genetic disorder characterized by the deficiency of the enzyme glucocerebrosidase. It contains eliglustat as its active ingredient, a substrate reduction therapy that reduces the accumulation of glucocerebroside in cells, thereby alleviating the symptoms of Gaucher disease.

Key Features:

• Substrate Reduction Therapy: Eliglustat acts as a substrate reduction therapy by inhibiting the enzyme glucosylceramide synthase, which is involved in the synthesis of glucocerebroside. By reducing the production of glucocerebroside, eliglustat helps to decrease the accumulation of this lipid in cells, thereby addressing the underlying cause of Gaucher disease.
• Treatment of Gaucher Disease: Eliglustat Oleptiss FCT 180/360 MG Tablet is indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers as detected by an FDA-cleared test.
• Oral Administration: Eliglustat Oleptiss FCT 180/360 MG Tablet is administered orally, typically once or twice daily, depending on the individual patient’s dose regimen. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical studies have demonstrated the efficacy of eliglustat in reducing spleen and liver volume, improving hemoglobin levels, and reducing biomarkers of Gaucher disease activity in patients with Gaucher disease type 1. It offers a valuable treatment option for patients with this rare genetic disorder.
• Safety Profile: Eliglustat has a manageable safety profile, with common side effects including headache, fatigue, nausea, diarrhea, and back pain. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively.
• Patient Education: Patients prescribed Eliglustat Oleptiss FCT 180/360 MG Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Eliglustat Oleptiss FCT 180/360 MG Tablet should be initiated and monitored by a qualified healthcare provider experienced in the management of Gaucher disease. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Eliglustat Oleptiss FCT 180/360 MG Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to innovative medications is crucial to improving patient outcomes and quality of life for those with rare genetic disorders like Gaucher disease.

Additional information